Enriched Hematopoetic Stem Cell Infusion ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 19 | Lysosomal storage disease | 1 |
| 284 | Diamond-Blackfan anemia | 1 |
19. Lysosomal storage disease
Clinical trials : 899 / Drugs : 684 - (DrugBank : 99) / Drug target genes : 51 - Drug target pathways : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02021266 (ClinicalTrials.gov) | April 2013 | 19/12/2013 | Single Patient Expanded Access Protocol: Metabolic Boost | Single Patient Expanded Access Protocol: Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders | Metachromatic Leukodystrophy | Biological: Enriched Hematopoetic Stem Cell Infusion | Talaris Therapeutics Inc. | Duke University | No longer available | N/A | N/A | Female | Phase 1/2 | United States |
284. Diamond-Blackfan anemia
Clinical trials : 36 / Drugs : 95 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01419704 (ClinicalTrials.gov) | May 2011 | 16/8/2011 | Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies | Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies | Anemia, Sickle Cell;Complex and Transfusion-dependent Hemoglobinopathies;Thalassemia;Diamond-Blackfan Anemia;Bone Marrow Failure Syndromes;Alpha-Thalassemia;Beta-Thalassemia | Biological: Enriched Hematopoetic Stem Cell Infusion | Talaris Therapeutics Inc. | Duke University | Withdrawn | N/A | 45 Years | All | 0 | Phase 1/Phase 2 | United States |